



# PROMISS

DIAGNOSTICS

**EARLY DETECTION MADE SIMPLE**



# INVESTMENT OPPORTUNITY

## DE-RISKED TECHNOLOGY & REGULATORY PATHWAY

- ◆ **NISA Reveal™** is an AI-enabled blood-based risk assessment test to identify ovarian cancer
- ◆ **Validated on a multi-center** dataset, including **Mayo Clinic**
- ◆ **Efficient 510(k) regulatory pathway** identified leveraging retrospective data for submission

## SUBSTANTIAL COMMERCIAL OPPORTUNITY

- ◆ **80% margin** business addressing a **\$2.4B U.S.** underserved market
- ◆ **Low capital, 12-month timeline** to FDA clearance, product launch, and **revenue generation**
- ◆ **Rapid** commercial launch and reimbursement pathway using **existing CPT coding**

# OVARIAN CANCER 'SILENT KILLER' DEADLIEST GYNECOLOGICAL DISEASE

65%

Diagnosed stage III, IV

54%

Die within five years



## BECAUSE ...



No approved screening tests




Poor performance of diagnostic tests



Lack of accessibility to specialists

# NISA REVEAL™ ADVANCES EARLY OVARIAN CANCER DETECTION

NISA Reveal™ merges traditional pathology testing with patient clinical data and AI



# NISA REVEAL™ HAS HIGH PREDICTIVE ACCURACY

Retrospective multi-cohort analysis on 1,544 patients confirms strong performance in detecting OVCA

98%

Sensitivity for **early-stage** ovarian cancer

91%

Sensitivity across all ovarian cancer stages

34k


Reduction of unnecessary major surgeries per year

## VALIDATION SUMMARY

- ✓ **Trained and validated on > 1500 patients** across multiple centers
- ✓ **Consistent performance** across training and validation sets
- ✓ **Strong potential clinical impact** due to the high performance of early-stage diagnosis

# REVENUE FLOW FOR PROMISS DIAGNOSTICS

PROMISS Diagnostics generates revenue through existing CPT code and established reimbursement pathway



**PAYMENT RATES FOR EXISTING CPT CODE IS \$897 (CMS)  
AND AVERAGE OF \$1,200 (PRIVATE PAYERS)**

# LARGE MARKET AND SIGNIFICANT UNMET NEED

NISA SUITE™ solves at least three unmet needs in ovarian cancer diagnosis

## > \$2.4B

Total Addressable Market in USA

### > \$560M



Diagnostic  
Tool

(> 750k tests)

### > \$600M



Active  
Surveillance

(> 2M tests)

### > \$1.3B



Risk  
Stratification

(> 20M tests)

## LARGE POTENTIAL EXPANDED OPPORTUNITY

outside USA market

# EXPERIENCED AND MOTIVATED MANAGEMENT TEAM

## MANAGEMENT TEAM



**Jalal Sulaiman**

MS, MSEE, BB6 $\sigma$ , MBA

**CEO/Co-founder**

15 years of strategic planning and organization management in healthcare industry

MBA, University of Chicago

Received GE President Award



**Roa Qato**

MD, OB/GYN

**Chief Medical Officer /  
Co-founder**

>15 years of clinical experience in academic and private practice

Best Surgeon for PGY-3

Winner of the Jerome J. Hoffman Award

## R&D TEAM



**Yolanda Hagar**

PhD

**Chief Data Scientist**

Experienced in protein biomarker discovery and clinical diagnostics industry

# EXPERIENCED ADVISORY BOARD



**Stephen Coutts**, PhD, MBA  
**Business/Scientific Advisor**

43 years in life science, seasoned entrepreneur  
Product development strategy



**Ellen Rudnick**, MBA  
**Business Advisor**

20 years in healthcare industry  
Strong network in life science, Health Systems and VCs



**Ian Gunsolus**, PhD  
**Scientific Advisor;**  
**Lab Chemistry Advisor**

Medical Laboratory Scientific Director at HealthPartners;  
Board certified in clinical chemistry



**Lisa Anselmino**, PhD  
**Business Development Advisor**

30 years in dx industry  
Business and partnership development  
Strong network in diagnostics



**John Jedziniak**, MBA  
**Technology Advisor**

>20 years experience in medical device, AI, EMR and data connectivity



**Ilke Panzer**, MSE  
**Business Strategy Advisor**

>30 years experience in diagnostics;  
CEO Greiner Bio-One International  
Former SVP of diagnostic laboratories at BloodCenter



# \$5.0M SERIES A FUNDING TO CLINICAL LAUNCH OF NISA REVEAL TEST

## ACHIEVED MILESTONES

### Partnership

Partnered with world-renowned institutions; model validated on ~2,000 patients

### FDA Pre-submission

Completed FDA pre-submission meeting; accelerated 510k clearance path

### Locked PROMISS Model

NISA Reveal™ Algorithm was validated, locked and ready for 510k process

## TARGET SERIES A ROUND \$5.0M

### FDA 510(K) Clearance

Conduct retrospective clinical trials with 775 patients across 3 sites

### Market Development

Launch educational marketing campaigns  
CMS and private insurance coverage

### Product Development

Implement a business operating model using a cloud computing platform

**Non-invasive test**  
with high sensitivity for  
early detection

**Patented technology**  
to address large  
unmet needs

**Fast path** to product  
approval/launch based on  
existing clinical POC; exit  
opportunities with high ROI

**CONTACT**



**PROMISS**  
DIAGNOSTICS

**JALAL SULAIMAN**

President and CEO

[Jalal.sulaiman@promissdx.com](mailto:Jalal.sulaiman@promissdx.com)